Anas Platyrhynchos Feather Anemone Pulsatilla Anse

證據等級: L5

預測適應症: 0 個

Multi-Allergen & Homeopathic Complex (28 Ingredients): No Repurposing Prediction Available

One-Sentence Summary

This candidate is a 28-ingredient complex comprising animal epithelial allergens (duck, goose, cat, dog, horse, rabbit, hamster, mouse, guinea pig, pig, cow, sheep, chicken, turkey feathers/hair/skin/dander), cockroach, homeopathic botanicals (Anemone pulsatilla, Strychnos nux-vomica seed), and homeopathic minerals (Arsenic trioxide, Phosphorus, Sulfur); it is not approved or marketed in Taiwan and has no identifiable single INN or DrugBank entry. The TxGNN pipeline returned no predicted indications for this candidate, and no original approved indications were identified. A repurposing evaluation cannot be completed at this stage — a Hold decision is warranted pending fundamental data remediation.

Quick Overview

Item	Content
Original Indication	Not identified
Predicted New Indication	No predictions available
TxGNN Prediction Score	N/A
Evidence Level	N/A — no predictions generated
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

US Market Information

No authorizations were found for this 28-ingredient complex. The TFDA query returned 0 records, and no matching NDA/ANDA/BLA was identified.

Note on ingredient Arsenic Trioxide: As a standalone drug, Arsenic Trioxide (Trisenox) holds FDA approval for relapsed/refractory acute promyelocytic leukemia (APL). However, in this context it appears as one component of a multi-ingredient preparation alongside allergens and classical homeopathic minerals, consistent with a homeopathic dilution rather than a therapeutic oncologic dose. If the concentration in this product is in fact pharmacologically active (i.e., not ultra-diluted), the candidate should be re-evaluated separately under an oncology repurposing framework.

Safety Considerations

Please refer to the package insert for safety information.

Specific concern — Arsenic Trioxide component: At therapeutic concentrations, arsenic trioxide carries Black Box Warnings for QTc prolongation, APL differentiation syndrome, and cardiac arrest. Until the formulation concentration is confirmed, this risk cannot be assessed or dismissed.

Conclusion and Next Steps

Decision: Hold

Rationale: The pipeline could not match this 28-ingredient complex to a single DrugBank ID, produced zero TxGNN repurposing predictions, and found no regulatory authorizations or safety data — there is no actionable evidence base on which to conduct a repurposing evaluation.

To proceed, the following is needed:

Identify the commercial product name to determine whether this is a registered allergen immunotherapy preparation, a homeopathic OTC product, or a combination of both; this determines which regulatory and evidence framework applies
Confirm the product category — if this is a homeopathic preparation, standard TxGNN DrugBank-based repurposing methodology is not applicable and the evaluation should be closed or re-scoped
Resolve DrugBank mapping — obtain a DrugBank ID for the primary active ingredient(s) so that TxGNN can generate predictions; for mixtures, evaluate each pharmacologically active component individually
Obtain the original approved indication from any existing product label or regulatory filing
Retrieve MOA data for the key active components, particularly Arsenic Trioxide and Strychnos nux-vomica alkaloids
Clarify Arsenic Trioxide concentration — if present at therapeutic (non-homeopathic) levels, initiate a separate evaluation under oncology/hematology repurposing workflows and apply full cytotoxicity and cardiac safety assessment
Download and parse the package insert (if available) for warnings, contraindications, and drug interactions before advancing to any safety screening step
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.